Sanofi stock edges lower as RBC starts coverage with EUR 80 target

Sanofi stock (ISIN FR0000127771) was trading at around EUR 74.13 on Euronext Paris on September 9, 2026, slightly below the prior close as investors digested a new analyst view from RBC Capital with an EUR 80.00 price target on the shares. According to Investing.com on September 9, 2026, RBC Capital started coverage with a Sector Perform rating, citing transition risks and setting its target about 7.9 percent above the latest Euronext price.

RBC Capital sees limited catalysts

RBC Capital’s initiation gives investors a fresh benchmark for Sanofi’s valuation just as the stock trades in the low EUR 70s. According to Investing.com, the bank initiated Sanofi with a Sector Perform recommendation and an EUR 80.00 price target, highlighting near term challenges from limited catalysts and transition risks in the portfolio.

The RBC view adds to a series of neutral stances on Sanofi. As TipRanks reported on September 8, 2026, RBC Capital’s analyst noted that Sanofi faces a patent cliff for its key Dupixent drug and skepticism on delivering future pipeline sales, even as the strategic thesis evolves under CEO Belen Garijo. This combination of an EUR 80.00 target and concerns about long term patent and pipeline risks underpins the cautious tone despite some upside relative to current prices.

Price and valuation context for Sanofi stock

On the market side, Sanofi’s reference listing is on Euronext Paris under the ticker SAN. Per data from Zonebourse, the shares last traded at EUR 74.13 on September 9, 2026, down 0.76 percent on the day, after a prior close at EUR 74.70 on September 8, 2026. That places the price modestly below the average analyst target around the low-to-mid EUR 90s range and under the EUR 80.00 target introduced by RBC Capital.

The current price also sits in the context of a broader range over recent months. According to Zonebourse on September 9, 2026, the last closing price was EUR 74.70, while the average price objective from 24 analysts stands at EUR 94.45, implying about 26.4 percent potential upside if consensus proves correct. In the same overview the average recommendation is described as Accumulate, showing that while individual houses like RBC Capital are cautious, the broader sell side still sees upside versus current levels.

Analyst targets frame the risk profile

Beyond RBC Capital’s new coverage, several other banks have recently reiterated their views on Sanofi. As The Globe and Mail reported on September 9, 2026, Barclays maintained a Hold rating on Sanofi with an EUR 83.00 price target, while Bank of America Securities reaffirmed a Hold stance with a EUR 92.00 target in a report dated September 4, 2026.

These targets frame a valuation corridor for investors: EUR 80.00 from RBC, EUR 83.00 from Barclays and EUR 92.00 from Bank of America all sit above the latest EUR 74.13 Euronext price, but they cluster below the roughly EUR 94.45 consensus objective cited by Zonebourse. From an investor perspective, the key takeaway is that banks see upside from current levels but hesitate to assign a more aggressive rating because of patent expiries and the need to deliver future pipeline growth.

Stock performance and trading metrics

Sanofi’s recent trading performance adds another layer to the picture. Per the real time Euronext Paris data summarized by Zonebourse, the stock is down about 3.9 percent over the past five trading days and roughly 10.4 percent since the start of the year as of September 9, 2026. On September 9, 2026, around 339,626 shares changed hands, compared with about 1,468,180 shares on September 8, 2026, indicating a lower volume session as the market absorbed the RBC coverage.

While the exact 52-week high and low are not detailed in the latest week filtered sources, the combination of year to date performance and consensus targets shows that Sanofi is trading meaningfully below levels that analysts expect over the medium term. In effect, the roughly EUR 74.13 price as of September 9, 2026 sits about 26.4 percent beneath the EUR 94.45 average objective cited by Zonebourse, a gap that signals both potential upside and the need for confidence in execution.

Closing view on Sanofi stock price

At the time of the latest Euronext Paris snapshot on September 9, 2026, Sanofi stock was quoted at EUR 74.13, down 0.76 percent from the previous close of EUR 74.70, with trading concentrated on its primary listing under the SAN ticker. For investors, that level positions the shares below the new EUR 80.00 RBC Capital target and well under the average analyst objective around EUR 94, underscoring how future pipeline delivery and management of patent risks will be central to whether the stock can close this valuation gap.

More news and analyses on Sanofi stock